1071433-01-6 Usage
Description
Methyl 2-methylindazole-6-carboxylate, also known as 2-Methyl-2H-indazole-6-carboxylic Acid Methyl Ester, is a synthetic intermediate with potential applications in the pharmaceutical industry. It is an analog of Indazole-3-carboxylic Acid Methyl Ester (I505250) and is characterized by its unique chemical structure, which allows for various modifications and functionalization.
Uses
Used in Pharmaceutical Industry:
Methyl 2-methylindazole-6-carboxylate is used as a synthetic intermediate for the development of N-benzoylindazole derivatives and analogues. These compounds have potential applications as inhibitors of human neutrophil elastase, an enzyme involved in various inflammatory processes and diseases.
Additionally, Methyl 2-methylindazole-6-carboxylate is used in the preparation of indazole-pyridine based protein kinase/Akt inhibitors. Akt, also known as protein kinase B, is a serine/threonine-specific protein kinase that plays a crucial role in cellular survival, growth, and angiogenesis. Inhibiting Akt has been shown to have potential therapeutic benefits in various cancer types.
Check Digit Verification of cas no
The CAS Registry Mumber 1071433-01-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,7,1,4,3 and 3 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1071433-01:
(9*1)+(8*0)+(7*7)+(6*1)+(5*4)+(4*3)+(3*3)+(2*0)+(1*1)=106
106 % 10 = 6
So 1071433-01-6 is a valid CAS Registry Number.
1071433-01-6Relevant articles and documents
HISTONE DEMETHYLASE INHIBITORS
-
Paragraph 00477; 00478, (2014/06/24)
Provided herein are substituted pyrazolylpyridine, pyrazolylpyridazine, and pyrazolylpyrimidine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
ORNITHINE DERIVATIVE
-
Page/Page column 24; 36, (2010/01/29)
Provided is a compound which is useful as a therapeutic agent for chronic renal insufficiency and a therapeutic agent for diabetic nephropathy. The present inventors have made extensive studies on an ornithine derivative having an antagonistic action against an EP4 receptor, and as a result, they have found that by introducing cycloalkanediyl at a C terminal of the ornithine part of the compound of the present invention, the physicochemical properties such as solubility, and the like can be improved, thereby giving further preferred properties as a pharmaceutical. Therefore, they have completed the present invention. The compound of the present invention exhibits a good antagonistic action against an EP4 receptor, and thus, it is useful as a therapeutic agent for chronic renal insufficiency and diabetic nephropathy.